Health411-Cancer Therapeutics with Greg Bosch

from Health411 · host Dr. Jonathan Karp

In this episode of Health411, host Dr. Jonathan Karp and producer Daniel Geller discuss Panavance Therapeutics with Chairman and CEO Greg Bosch. Panavance is focused on the compound GP-2250, a molecule with broad applications in cancer treatment. During the interview, Mr. Bosch elaborates on the groundbreaking potential of GP-2250, explaining how it targets specific cancer cells while minimizing damage to healthy tissue. He also shared insights into Panavance's rigorous clinical trials and its commitment to advancing personalized therapies for cancer patients. Tune in to learn more about the promising future of GP-2250 and its potential to revolutionize cancer treatment.

Episode metadata supplied by the publisher feed · Published Oct 15, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Health411-Cancer Therapeutics with Greg Bosch

0:00 43:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Health411?

This episode is 43 minutes long.

When was this Health411 episode published?

This episode was published on October 15, 2023.

Can I download this Health411 episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!